My Portfolio

Biohaven Ltd BHVN:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 06/03/26 EDT

10.74

-0.07 (-0.65%)

Volume

5,967

10.81

+0.68 (+6.71%)

Volume

3,101,079

52 week range

7.48 - 18.57

Open9.96
Day High10.83
Day Low9.90
Prev Close10.81
52 Week High18.57
52 Week High Date10/30/25
52 Week Low7.48
52 Week Low Date11/11/25

Latest On Biohaven Ltd

Mizuho's Jared Holz on pharma's reaction to FDA changeMay 13, 2026CNBC.com
FDA head resigning boosts healthcare stocks short-term, but still a lot of unknowns: Mizuho's HolzMay 12, 2026CNBC.com
Goldman Sachs says this under-the-radar biotech play could more than double in valueFebruary 8, 2026CNBC.com
Friday's biggest analyst calls: Nvidia, Amazon, Micron, Reddit, Roblox, Estee Lauder, Palantir February 6, 2026CNBC.com
This biotech stock has plummeted over the past year. RBC sees big turnaround aheadJanuary 21, 2026CNBC.com
Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim CramerJanuary 14, 2026CNBC.com
Lightning Round: Opendoor is high, but the company makes no money, says Jim CramerNovember 21, 2025CNBC.com

Key Stats

Market Cap1.628B
Shares Out150.56M
10 Day Average Volume2.94M
Dividend-
Dividend Yield-
Beta3.30

Latest On Biohaven Ltd

Mizuho's Jared Holz on pharma's reaction to FDA changeMay 13, 2026CNBC.com
FDA head resigning boosts healthcare stocks short-term, but still a lot of unknowns: Mizuho's HolzMay 12, 2026CNBC.com
Goldman Sachs says this under-the-radar biotech play could more than double in valueFebruary 8, 2026CNBC.com
Friday's biggest analyst calls: Nvidia, Amazon, Micron, Reddit, Roblox, Estee Lauder, Palantir February 6, 2026CNBC.com
This biotech stock has plummeted over the past year. RBC sees big turnaround aheadJanuary 21, 2026CNBC.com
Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim CramerJanuary 14, 2026CNBC.com
Lightning Round: Opendoor is high, but the company makes no money, says Jim CramerNovember 21, 2025CNBC.com

KEY STATS

Open9.96
Day High10.83
Day Low9.90
Prev Close10.81
52 Week High18.57
52 Week High Date10/30/25
52 Week Low7.48
52 Week Low Date11/11/25
Market Cap1.628B
Shares Out150.56M
10 Day Average Volume2.94M
Dividend-
Dividend Yield-
Beta3.30

RATIOS/PROFITABILITY

EPS (TTM)-5.67
P/E (TTM)-1.91
Fwd P/E (NTM)-3.97
EBITDA (TTM)-644.203M
ROE (TTM)-333.00%
Revenue (TTM)-
Gross Margin (TTM)-
Net Margin (TTM)-
Debt To Equity (MRQ)186.80%

EVENTS

Earnings Date08/10/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Biohaven initiates first-in-human dosing for BHV-8100June 1, 2026TipRanks
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX)May 30, 2026TipRanks
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO)May 29, 2026TipRanks
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN) and Healthequity (HQY)May 29, 2026TipRanks
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)May 28, 2026TipRanks

Profile

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; Molecular Degrader of Extracellular Proteins (MoDE) and...

Vlad Coric M.D.

Chairman of the Board, Chief Executive Officer

Matthew Buten

Chief Financial Officer

Address

215 Church Street

New Haven, CT

06510

United States

https://www.biohaven.com/